Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Trip.com Group Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Trip.com Group Ltd trades at $45.86 (market cap $29.10B). The key difference: Alnylam Pharmaceuticals, Inc. and Trip.com Group Ltd are close in size by market cap, and Trip.com Group Ltd pays a 0.42% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TCOM | |
|---|---|---|
Market Cap | $29.60B | $29.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $78.96 |
52-Week Low | $205.48 | $39.84 |
Enterprise Value | $27.56B | $21.75B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Trip.com (TCOM) trades at $47.12, up 2.12% today, with a bullish technical signal from moving averages and strong fundamentals including a P/E of 6.89 and net income margin of 48.65%. Recent Q2 2026 earnings guidance missed expectations, and the company accepted a $770 million antitrust penalty in China (Reuters, 2026-07-24), creating near-term uncertainty despite robust revenue growth trends from $20.0B in 2022 to $62.4B in 2025.
The stock offers value with low valuation multiples and high profitability, but regulatory risks and muted Q2 guidance pressure upside. Analyst consensus is bullish with a $59.29 price target (67.44% buy ratings), though institutional selling and antitrust concerns warrant caution for investors seeking exposure to China's travel recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
